<DOC>
	<DOC>NCT01935700</DOC>
	<brief_summary>This trial is to evaluate the potential of colchicine for the palliative management of hepatocellular carcinoma patients with distant metastasis or large vessel invasion using the Department of Health R.O.C. approved doses and methods of administration.</brief_summary>
	<brief_title>Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>1. . Patient has at least one of the following criteria: (1) positive for hepatocellular carcinoma evidenced by cytology or pathology, (2) serum alphafetoprotein level &gt; 400 ng/mL and has evidence of hepatocellular carcinoma provided by contrastenhanced computed tomography or magnetic resonance imaging. 2. . Contrastenhanced computed tomography or magnetic resonance imaging has evidence of distant metastasis or large vessel invasion caused by hepatocellular carcinoma. 3. . Patient has Child A hepatic reserved function 1. . There are lifethreatening hemorrhage including gastrointestinal hemorrhage and hemorrhage from other vital organs such as lungs or brain. 2. . There are lifethreatening bacterial, fungal or viral infection (not included hepatitis B and C virus). 3. . Patient has serum creatinine level &gt; 1.5 mg/dL. 4. . Patient must receive longterm medication of statin or fibrates drugs and these medications can not be changed. 5. . Patient has white blood cell count &lt; 1500/µL, platelet count &lt; 30000/µL or hemoglobin &lt; 9.0 gm/dL after medication. 6. . Pregnant woman or plan to be a pregnant woman 7. . allergy to colchicine or has history of severe side effects caused by colchicine 8. . Patient has received systemic chemotherapy within 2 months before enrollment or plans to receive systemic chemotherapy in the future. 9. . Patient is under or plans to receive Nexavar or other clinical trial testing drug. 10. . Patient has severe malfunction of vital organs and can not participate in this study justified by the doctor in this research team. 11. . Patient is under or plans to receive Chinese traditional medicine or herb drugs.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>colchicine</keyword>
</DOC>